Cost of Risk (COR)

Type: Public
On the web: http://www.cortexpharm.com
Employees: 13
Employee growth: (51.9%)

Cortex Pharmaceuticals develops drugs to treat neurodegenerative and psychiatric disorders. Its research focuses on the AMPA receptor, which facilitates communication between nerve cells; the firm's Ampakine compounds may enhance this receptor's activity. Its lead drug candidate is CX717, which it is developing for a number of indications including respiratory depression (a potentially fatal side effect of some anesthetics and post-surgical painkillers), Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), and daytime sleepiness. The firm believes Ampakine drugs may also be helpful in treating a variety of other brain-related disorders, including depression, autism, and Huntington's disease.

Key numbers for fiscal year ending December, 2008:
Sales: $0.0M
Net income: ($14.6)M

Officers:
Chairman: Roger G. Stoll
President, CEO, and Director: Mark A. Varney
VP, CFO, Corporate Secretary, and Controller: Maria S. Messinger

Competitors:
Cephalon
Eli Lilly
Shire

Quantitative measurement of the total costs (losses, risk control costs, risk financing costs, and administration costs) associated with the Risk Management function, as compared to a business's sales, assets, and number of employees. The purpose of such a comparison is to determine whether the total costs of the risk management function are increasing, decreasing, or remaining constant as a function of the business's economic activity. After the quantitative measurement has been derived, a comparison can be made between the COR of that business and the CORs of its peer groups. In addition, COR will allow the business to focus on the areas of operation that will have the greatest long-term effects on its total risk management function costs.

(Fr.)

HORN.